Skip to main content
Premium Trial:

Request an Annual Quote

Genetics Institute Will Offer GeneChips to DiscoverEase Customers

Premium

SANTA CLARA, Calif.--Affy metrix here has signed a three-year, nonexclusive agreement that will allow Genetics Institute to offer its DiscoverEase customers Affymetrix's GeneChip expression-monitoring probe arrays. The DiscoverEase program is a molecular biology initiative designed to build a library containing novel, human secreted proteins. Genetics Institute was a codeveloper of the GeneChip technology.

Genetics Institute said it will use the arrays to monitor expression levels of thousands of genes for identifying and selecting drug discovery research targets. It will also gain the right to develop and sell access subscriptions to a gene expression database developed using customized GeneChip probe arrays. In addition, Affymetrix agreed to supply GeneChips designed to analyze DiscoverEase genes to DiscoverEase customers.

Affymetrix will receive annual subscription fees in excess of $4 million for use of the GeneChip technology and access to related database information by Discov erEase customers. The company will also be paid custom design and per-chip fees for supplying the Disco verEase GeneChips.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.